HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia — Stella

Home/Human Papillomavirus Type 16/

View on ClinicalTrials.gov

Recruiting

Back to Human Papillomavirus Type 16 trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

United States

University of Alabama at Birmingham, Birmingham, Alabama

Johns Hopkins University, Baltimore, Maryland

Key details

Phase

Early testing

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

National Cancer Institute (NCI)

Enrollment target

~48 participants

Started

September 2020

Primary completion

December 2026

Age range

19 Years and older

Sex

Female only

Last updated August 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.